Target species
Atlantic salmon.
Indications for use
For the treatment of furunculosis (Aeromonas salmonicida) infection of Atlantic salmon.
Contraindications
Do not use in brood stock.
Special precautions for use
Use of the product should be based on susceptibility testing of the strain of bacteria isolated from the fish. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.
Chloramphenicol type antibacterials may prolong the effects of anaesthetics.
Operator warnings
Wear either a disposable half-mask respirator conforming to European standard EN 149 or a non-disposable respirator to European Standard EN 140 with a filter to EN 143, chemically resistant gloves, protective coveralls and goggles while incorporating the premix into the feed.
Wear gloves and do not smoke or eat while handling the product or medicated feed.
Wash hands thoroughly with soap and water after use of the product or medicated feed.
Thoroughly clean all equipment used in medicating feed.
Other precautions
In the UK, it is essential to obtain a discharge consent from the local regional office of the Environment Agency or SEPA.
Adverse reactions
None known.
Interactions
None known.
Amounts to be administered and administration route
In-feed use.
Dose: 10 mg/kg bodyweight.
The incorporation rate in feed must be calculated to achieve this dosage.
Affected fish should receive the medicated feed daily for 10 consecutive days.
The intake of medicated feed depends on the clinical condition of the fish. In order to ensure the correct dosage is administered the concentration of Florocol in feed must be adjusted accordingly.
Table: Examples of incorporation rates:
Feeding rate (as % of fish bodyweight) | Quantity (kg) of Florocol per tonne of medicated feed | Fish (kg) medicated daily per tonne of medicated feed |
0.5 | 4 | 200,000 kg |
1.0 | 2 | 100,000 kg |
2.0 | 1 | 50,000 kg |
Advice on correct administration
For incorporation into dry feed at a registered mill.
A manufacturer who is approved to incorporate veterinary medicinal products, or premixtures containing such products, directly at any concentration must be responsible for mixing when incorporation is less than 2 kg per tonne for final feed.
The premix should be mixed with oil before incorporation into dry feed. To ensure thorough dispersion, the product should first be mixed with, or surface-coated onto, a suitable quantity of feed before incorporation in the final mix.
Overdose
No adverse effects were seen at up to ten times the recommended dose.
Withdrawal periods
150 degree days. (15 days from the last treatment at 10 °C)